

Remarks

Included herewith is a petition for a one-month extension of time and authorization to charge the required fee to an appropriate deposit account. The time for response is now set to expire on December 5, 2004.

Restriction to one of the following inventions has been required under 35 U.S.C. §121:


- I. Claims 1-3, 5 and 10 drawn to a composition and kit, classified in class 514, subclass 9.
- II. Claims 6 and 11 drawn to a method for treating xenograft rejection, classified in class 514, subclass 885.
- III. Claims 7-9 drawn to a method of extracorporeal treatment, classified in class 424, subclass 140.1.

Applicants hereby elect Group I, claims 1-3, 5 and 10, without traverse. Accordingly, the claims of Group III, i.e., claims 7-9 has been cancelled and Applicants reserve the right to prosecute said claims in one or more divisional applications. The claims of Group II, i.e., claims 6 and 11, may be rejoined under the provisions of MPEP §821.04 and therefore have not been cancelled.

This paper is believed to be fully responsive to the Office Action. Early action on the merits is respectfully requested.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080


Thomas R. Savitsky
Attorney for Applicants
Reg. No. 31,661
(862) 778-7909

TRS/ld

Date: December 2, 2004